Inhibition of human immunodeficiency virus-1 infectivity in human cells

US5668149A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Stephen Oroszlan · Potomac, US
• Wen-Po Tsai · Walkersville, US
• Peter L. Nara · Frederick, US
• Hsiang-Fu Kung · Verona, US

Key dates

• Filing date: Jan 26, 1990
• Grant date: Sep 16, 1997
• Expiry date: Jan 26, 2010

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/47
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including amodiaquin, chloroquine, hydroxychloroquine, primoquine, quinacrine and compounds having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen, or join to form a cyclic structure of the formula: ##STR2## and R.sup.3 and R.sup.4, same or different, are hydrogen, C.sub.1 -C.sub.8 lower alkyl or hydroxy substituted C.sub.1 -C.sub.8 lower alkyl, and the pharmaceutically acceptable salts thereof.